To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.


Already Have an Account?

Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
OE Original Cover

Platelet-rich Plasma (PRP) Versus Corticosteroid Injection for Painful Shoulder Conditions: Powered by OE M.I.N.D.

Cite This
+ Favorites
Cite This
+ Favorites
December 19, 2022

Platelet-rich Plasma (PRP) Versus Corticosteroid Injection for Painful Shoulder Conditions: Powered by OE M.I.N.D.

Vol: 5| Issue: 12| Number:3| ISSN#: 2563-559X

Authored By: Yaping Chang, Steve Phillips, Meng Zhu, Aiden Scholey & Mohit Bhandari on Behalf of OrthoEvidence.

Banner Image
  • OE M.I.N.D. contains data from 764 randomized controlled trials (RCTs) related to shoulder conditions with over 122,000 patients, and is a powerful and efficient tool to auto generate evidence reports regarding a clinical topic.
  • For shoulder conditions, corticosteroid injection demonstrates short-term (within 6 weeks) effectiveness in composite clinical outcomes and pain compared with platelet-rich plasma (PRP) injection.
  • PRP injection demonstrates superior outcomes in composite clinical outcomes compared with corticosteroid injection in follow-up duration of 3 to 6 months. There is no significant difference between PRP and corticosteroid injection in composite clinical outcomes in two follow-up periods: 6 weeks to 3 months, and 6 to 24 months.
  • Beyond 6 weeks post treatment, PRP injection shows superior outcomes in pain compared with corticosteroid injection.
  • There is no difference between PRP and corticosteroid injection in incidence of conversion to surgery or adverse events at the longest follow-up.
  • There are 10 studies aiming to recruit 628 patients currently ongoing studies that investigates the effects of PRP or corticosteroid injection in treating shoulder conditions using data from
  • In most published studies related to corticosteroid injection for shoulder conditions, incidence of adverse events and a follow-up of 6 months are reported.
  • Since 2011, the manufacturers that have published the most research associated with PRP or corticosteroid for shoulder conditions are Zimmer-Biomet, Pfizer, Regen Lab, Arthrex, Actavis and Terumo.
Shoulder pain affects 1 in 4 people and is associated with impared life quality and function in work and household activities (Luime et al., 2004). Lifetime prevalence of shoulder pain ranges from 7% to 67% and for individuals whose work involves more upper limb activity and whose age is over 50, the prevalence is even higher, up to 78% ...
OE OriginalPreview Image



Join the Conversation

Please Login or Join to leave comments.

Jeffrey Bogosian 2022-12-26

Orthopaedic Surgeon - United States

I would like to see a Study that repeats PRP at 6months to see if serial treatment is more effective.